Sanling Huang1, Mengying Liao2, Siliang Chen1, Ping Zhang1, Fangzhou Xu1,3, Hongyu Zhang1,3. 1. Department of Hematology, Peking University Shenzhen Hospital Shenzhen 518000, Guangdong, P. R. China. 2. Department of Pathology, Peking University Shenzhen Hospital Shenzhen 518000, Guangdong, P. R. China. 3. The Clinical Trail Institute, Peking University Shenzhen Hospital Shenzhen 518000, Guangdong, P. R. China.
Abstract
BACKGROUND: Cutaneous T-cell lymphoma (CTCL) is highly heterogeneous, and its prognosis is closely related to the disease stage. The tumor microenvironment (TME) is an important component of tumor tissue, driving cancer cell growth, progression, and metastasis. However, the diagnostic value of TME in CTCL has not yet been studied in-depth. To date, no study has performed a comprehensive evaluation of the significance of the TME in CTCL. METHODS: Using xCell methods based on bulk RNA sequencing data, we inferred immune cell fraction in the TME in 126 patients and assessed the prognostic importance of immune cells. Consensus clustering was performed to determine the TME subtypes and characterize the transcriptome of each subtype. Based on the TME subtypes, we established the disease progression model using random forest algorithms and logistic regression. The efficacy of the model was examined using an additional 49-patient cohort. Finally, we validated our finding at the protein level using immunochemistry in a 16-patient cohort. RESULTS: Patients with advanced CTCL presented with a more active immunity overall than those with early stage. Random forest algorithms revealed that the immune cells CD4, macrophages, and dendritic cells (DCs) were the most effective prognosis predictors. Therefore, we constructed a risk model using logistic regression based on these immune cells. The TME score could be used to effectively predict disease conditions in three datasets with the AUC of 0.9414, 0.7912, and 0.7665, respectively. Immunochemistry at the protein level revealed that helper T cells and the macrophage markers CD4 and CD68 could successfully distinguish different CTCL stages in patients, whereas the DC marker langerin showed no change with disease progression. CONCLUSION: We found advanced-stage CTCL was associated with an active immune microenvironment, and the immune signatures CD4 and CD68 showed a relatively high accuracy in predicting CTCL disease progression. AJTR
BACKGROUND: Cutaneous T-cell lymphoma (CTCL) is highly heterogeneous, and its prognosis is closely related to the disease stage. The tumor microenvironment (TME) is an important component of tumor tissue, driving cancer cell growth, progression, and metastasis. However, the diagnostic value of TME in CTCL has not yet been studied in-depth. To date, no study has performed a comprehensive evaluation of the significance of the TME in CTCL. METHODS: Using xCell methods based on bulk RNA sequencing data, we inferred immune cell fraction in the TME in 126 patients and assessed the prognostic importance of immune cells. Consensus clustering was performed to determine the TME subtypes and characterize the transcriptome of each subtype. Based on the TME subtypes, we established the disease progression model using random forest algorithms and logistic regression. The efficacy of the model was examined using an additional 49-patient cohort. Finally, we validated our finding at the protein level using immunochemistry in a 16-patient cohort. RESULTS: Patients with advanced CTCL presented with a more active immunity overall than those with early stage. Random forest algorithms revealed that the immune cells CD4, macrophages, and dendritic cells (DCs) were the most effective prognosis predictors. Therefore, we constructed a risk model using logistic regression based on these immune cells. The TME score could be used to effectively predict disease conditions in three datasets with the AUC of 0.9414, 0.7912, and 0.7665, respectively. Immunochemistry at the protein level revealed that helper T cells and the macrophage markers CD4 and CD68 could successfully distinguish different CTCL stages in patients, whereas the DC marker langerin showed no change with disease progression. CONCLUSION: We found advanced-stage CTCL was associated with an active immune microenvironment, and the immune signatures CD4 and CD68 showed a relatively high accuracy in predicting CTCL disease progression. AJTR
Authors: Marc Van den Eynde; Bernhard Mlecnik; Gabriela Bindea; Tessa Fredriksen; Sarah E Church; Lucie Lafontaine; Nacilla Haicheur; Florence Marliot; Mihaela Angelova; Angela Vasaturo; Daniela Bruni; Anne Jouret-Mourin; Pamela Baldin; Nicolas Huyghe; Karin Haustermans; Annelies Debucquoy; Eric Van Cutsem; Jean-Francois Gigot; Catherine Hubert; Alex Kartheuser; Christophe Remue; Daniel Léonard; Viia Valge-Archer; Franck Pagès; Jean-Pascal Machiels; Jérôme Galon Journal: Cancer Cell Date: 2018-12-10 Impact factor: 31.743
Authors: Bethany Mundy-Bosse; Nathan Denlinger; Eric McLaughlin; Nitin Chakravarti; Susan Hwang; Li Chen; Hsiaoyin Charlene Mao; David Kline; Youssef Youssef; Rebecca Kohnken; Dean Anthony Lee; Gerard Lozanski; Aharon G Freud; Pierluigi Porcu; Basem William; Michael A Caligiuri; Anjali Mishra Journal: Blood Adv Date: 2018-08-14
Authors: Hasan H Danish; Shuling Liu; Jaymin Jhaveri; Christopher R Flowers; Mary J Lechowicz; Natia Esiashvili; Mohammad K Khan Journal: Leuk Lymphoma Date: 2016-04-22
Authors: Julia J Scarisbrick; H Miles Prince; Maarten H Vermeer; Pietro Quaglino; Steven Horwitz; Pierluigi Porcu; Rudolf Stadler; Gary S Wood; Marie Beylot-Barry; Anne Pham-Ledard; Francine Foss; Michael Girardi; Martine Bagot; Laurence Michel; Maxime Battistella; Joan Guitart; Timothy M Kuzel; Maria Estela Martinez-Escala; Teresa Estrach; Evangelia Papadavid; Christina Antoniou; Dimitis Rigopoulos; Vassilki Nikolaou; Makoto Sugaya; Tomomitsu Miyagaki; Robert Gniadecki; José Antonio Sanches; Jade Cury-Martins; Denis Miyashiro; Octavio Servitje; Cristina Muniesa; Emilio Berti; Francesco Onida; Laura Corti; Emilia Hodak; Iris Amitay-Laish; Pablo L Ortiz-Romero; Jose L Rodríguez-Peralto; Robert Knobler; Stefanie Porkert; Wolfgang Bauer; Nicola Pimpinelli; Vieri Grandi; Richard Cowan; Alain Rook; Ellen Kim; Alessandro Pileri; Annalisa Patrizi; Ramon M Pujol; Henry Wong; Kelly Tyler; Rene Stranzenbach; Christiane Querfeld; Paolo Fava; Milena Maule; Rein Willemze; Felicity Evison; Stephen Morris; Robert Twigger; Rakhshandra Talpur; Jinah Kim; Grant Ognibene; Shufeng Li; Mahkam Tavallaee; Richard T Hoppe; Madeleine Duvic; Sean J Whittaker; Youn H Kim Journal: J Clin Oncol Date: 2015-10-05 Impact factor: 44.544